Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors

BACKGROUND: Poly (ADP-ribose) polymerase (PARP) is essential for recognition and repair of DNA damage. In preclinical models, PARP inhibitors modulate topoisomerase I inhibitor-mediated DNA damage. This Phase I study determined the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharm...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: LoRusso, Patricia M., Li, Jing, Burger, Angelika, Heilbrun, Lance K., Sausville, Edward A., Boerner, Scott A., Smith, Daryn, Pilat, Mary Jo, Zhang, Jie, Tolaney, Sara M., Cleary, James M., Chen, Alice P., Rubinstein, Lawrence, Boerner, Julie L., Bowditch, Adam, Cai, Dongpo, Bell, Tracy, Wolanski, Andrew, Marrero, Allison M., Zhang, Yiping, Ji, Jiuping, Ferry-Galow, Katherine, Kinders, Robert J., Parchment, Ralph E., Shapiro, Geoffrey I.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4930710/
https://ncbi.nlm.nih.gov/pubmed/26842236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0652
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires